Vergote I B, van Dam P A, Laekeman G M, Keersmaeckers G H, Uyttenbroeck F L, Herman A G
Department of Gynecology, Sint Camillus Hospital (Antwerp University), Belgium.
Tumour Biol. 1991;12(5):261-6. doi: 10.1159/000217713.
In this prospective follow-up study the prognostic value of the tumor prostacyclin/thromboxane ratio in human breast carcinoma was investigated. The stable degradation products of prostacyclin and thromboxane (6-keto-PGF1 alpha and TXB2, respectively), were measured by radio-immunoassay in homogenized primary tumours from 29 patients with primary non-metastatic breast cancer. The median follow-up was 43 months (range 24-58 months). Patients with recurrent disease or patients who died of breast cancer had a significantly higher 6-keto-PGF1 alpha/TXB2 ratio than the disease-free survivors (p = 0.018 and p = 0.047, respectively). There was no significant difference in the 6-keto-PGF1 alpha and TXB2 levels. These data indicate that the prostacyclin/thromboxane balance in the tumour might be a prognostic factor in breast cancer. Prostanoid may contribute to metastasis in breast cancer, but the problem is complex because the different prostaglandins have numerous actions that may produce both undesirable and desirable effects.
在这项前瞻性随访研究中，对肿瘤前列环素/血栓素比值在人类乳腺癌中的预后价值进行了研究。通过放射免疫分析法，对29例原发性非转移性乳腺癌患者的原发性肿瘤匀浆中前列环素和血栓素的稳定降解产物（分别为6-酮-前列腺素F1α和血栓素B2）进行了测量。中位随访时间为43个月（范围24 - 58个月）。复发疾病患者或死于乳腺癌的患者，其6-酮-前列腺素F1α/血栓素B2比值显著高于无病生存者（分别为p = 0.018和p = 0.047）。6-酮-前列腺素F1α和血栓素B2水平无显著差异。这些数据表明，肿瘤中的前列环素/血栓素平衡可能是乳腺癌的一个预后因素。前列腺素可能在乳腺癌转移中起作用，但问题很复杂，因为不同的前列腺素有许多作用，可能产生不良和有益的影响。
